{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:27:38Z","timestamp":1793762858051,"version":"4.6.1"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This review examines the underlying mechanisms of disease pathogenesis in eosinophilic esophagitis with the aim of identifying how current and emerging therapies target specific pathologic pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Over the past three decades, the incidence and prevalence of EoE have risen significantly and it is now a leading cause of dysphagia and food impaction in both children and adults. Recent studies highlight how genetic predisposition, environmental exposures, epithelial barrier dysfunction, and abnormal type 2 immune responses interact to contribute to EoE pathogenesis. Key mechanisms include the release of epithelial alarmins, elevated type 2 cytokine signaling, and the recruitment of immune effector cells, all of which lead to chronic inflammation, tissue remodeling, and fibrostenosis. Current treatments include dietary management, proton pump inhibitors, swallowed corticosteroids, and dupilumab, the first approved biologic. New biologics and agents targeting the epithelial barrier, IL-13, TSLP, and related pathways offer hope for more personalized, mechanism-based therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Current therapies for EoE aim to reduce inflammation and prevent fibrostenotic complications, but challenges such as treatment nonresponse and long-term disease progression still exist. Mechanism-based therapies, particularly biologics targeting type 2 inflammatory pathways and barrier dysfunction, represent a promising frontier for more personalized treatment strategies. Understanding the interplay of immune signaling and epithelial dysfunction can inform the development of next-generation therapies with the potential to transform outcomes in EoE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11882-026-01253-w","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:48:47Z","timestamp":1773308927000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Eosinophilic Esophagitis: Mechanisms of Disease and Approach to Treatment"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5622-1345","authenticated-orcid":false,"given":"Ravi","family":"Gautam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2943-9944","authenticated-orcid":false,"given":"Melanie A.","family":"Ruffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"1253_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jaci.2011.02.040","volume":"128","author":"CA Liacouras","year":"2011","unstructured":"Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128:3\u201320.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR2","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/den.13786","volume":"33","author":"N Ishimura","year":"2021","unstructured":"Ishimura N, Okimoto E, Shibagaki K, Nagano N, Ishihara S. Similarity and difference in the characteristics of eosinophilic esophagitis between Western countries and Japan. Dig Endosc. 2021;33:708\u201319.","journal-title":"Dig Endosc"},{"key":"1253_CR3","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1016\/j.cgh.2023.06.005","volume":"21","author":"JW Hahn","year":"2023","unstructured":"Hahn JW, Lee K, Shin JI, Cho SH, Turner S, Shin JU, et al. Global incidence and prevalence of eosinophilic esophagitis, 1976\u20132022: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21:3270-3284.e77.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1253_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.cgh.2024.09.031","volume":"23","author":"HL Thel","year":"2025","unstructured":"Thel HL, Anderson C, Xue AZ, Jensen ET, Dellon ES. Prevalence and costs of eosinophilic esophagitis in the United States. Clin Gastroenterol Hepatol. 2025;23:272-280.e8.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1253_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/modpathol.2014.110","volume":"28","author":"ES Dellon","year":"2015","unstructured":"Dellon ES, Speck O, Woodward K, Covey S, Rusin S, Shaheen NJ, et al. Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy. Mod Pathol. 2015;28:383\u201390.","journal-title":"Mod Pathol"},{"key":"1253_CR6","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1053\/j.gastro.2007.08.017","volume":"133","author":"GT Furuta","year":"2007","unstructured":"Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment: sponsored by the American gastroenterological association (AGA) Institute and North American society of pediatric Gastroenterology, Hepatology, and nutrition. Gastroenterology. 2007;133:1342\u201363.","journal-title":"Gastroenterology"},{"key":"1253_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1053\/j.gastro.2017.06.067","volume":"154","author":"ES Dellon","year":"2018","unstructured":"Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology. 2018;154:319-332.e3.","journal-title":"Gastroenterology"},{"key":"1253_CR8","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1056\/NEJMra1502863","volume":"373","author":"GT Furuta","year":"2015","unstructured":"Furuta GT, Katzka DA. Eosinophilic esophagitis. N Engl J Med. 2015;373:1640\u20138.","journal-title":"N Engl J Med"},{"key":"1253_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cells12202473","volume":"12","author":"S Massironi","year":"2023","unstructured":"Massironi S, Mulinacci G, Gallo C, Elvevi A, Danese S, Invernizzi P, et al. Mechanistic insights into eosinophilic esophagitis: therapies targeting pathophysiological mechanisms. Cells. 2023;12:2473.","journal-title":"Cells"},{"key":"1253_CR10","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jaci.2014.07.021","volume":"134","author":"ES Alexander","year":"2014","unstructured":"Alexander ES, Martin LJ, Collins MH, Kottyan LC, Sucharew H, He H, et al. Twin and family studies reveal strong environmental and weaker genetic cues explaining heritability of eosinophilic esophagitis. J Allergy Clin Immunol. 2014;134:1084\u2013e10921.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/MPG.0b013e318290d15a","volume":"57","author":"ET Jensen","year":"2013","unstructured":"Jensen ET, Kappelman MD, Kim HP, Ringel-Kulka T, Dellon ES. Early life exposures as risk factors for pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2013;57:67\u201371.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1253_CR12","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s12016-018-8697-9","volume":"57","author":"PJ Dowling","year":"2019","unstructured":"Dowling PJ, Neuhaus H, Polk BI. The role of the environment in eosinophilic esophagitis. Clin Rev Allergy Immunol. 2019;57:330\u20139.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1253_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jaci.2018.04.015","volume":"142","author":"ET Jensen","year":"2018","unstructured":"Jensen ET, Dellon ES. Environmental factors and eosinophilic esophagitis. J Allergy Clin Immunol. 2018;142:32\u201340.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR14","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1111\/jgh.15921","volume":"37","author":"K Angerami Almeida","year":"2022","unstructured":"Angerami Almeida K, de Queiroz Andrade E, Burns G, Hoedt EC, Mattes J, Keely S, et al. The microbiota in eosinophilic esophagitis: A systematic review. J Gastroenterol Hepatol. 2022;37:1673\u201384.","journal-title":"J Gastroenterol Hepatol"},{"key":"1253_CR15","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/apt.70042","volume":"61","author":"I Spinelli","year":"2025","unstructured":"Spinelli I, Porcari S, Esposito C, Fusco W, Ponziani FR, Caruso C, et al. Meta-analysis: inverse association between Helicobacter pylori infection and eosinophilic oesophagitis. Aliment Pharmacol Ther. 2025;61:1096\u2013109.","journal-title":"Aliment Pharmacol Ther"},{"key":"1253_CR16","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jaci.2021.08.018","volume":"149","author":"X Chang","year":"2022","unstructured":"Chang X, March M, Mentch F, Nguyen K, Glessner J, Qu H, et al. A genome-wide association meta-analysis identifies new eosinophilic esophagitis loci. J Allergy Clin Immunol. 2022;149:988\u201398.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/ng.3033","volume":"46","author":"LC Kottyan","year":"2014","unstructured":"Kottyan LC, Davis BP, Sherrill JD, Liu K, Rochman M, Kaufman K, et al. Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease. Nat Genet. 2014;46:895\u2013900.","journal-title":"Nat Genet"},{"key":"1253_CR18","doi-asserted-by":"crossref","unstructured":"Davis BP, Stucke EM, Khorki ME, Litosh VA, Rymer JK, Rochman M et al. Eosinophilic esophagitis\u2013linked calpain 14 is an IL-13\u2013induced protease that mediates esophageal epithelial barrier impairment. JCI Insight [Internet]. 2016 [cited 2024 Apr 16];1. Available from: https:\/\/insight.jci.org\/articles\/view\/86355","DOI":"10.1172\/jci.insight.86355"},{"key":"1253_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26939-9","volume":"12","author":"T Shoda","year":"2021","unstructured":"Shoda T, Kaufman KM, Wen T, Caldwell JM, Osswald GA, Purnima P, et al. Desmoplakin and periplakin genetically and functionally contribute to eosinophilic esophagitis. Nat Commun. 2021;12:6795.","journal-title":"Nat Commun"},{"key":"1253_CR20","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.4049\/jimmunol.0903069","volume":"184","author":"C Blanchard","year":"2010","unstructured":"Blanchard C, Stucke EM, Burwinkel K, Caldwell JM, Collins MH, Ahrens A, et al. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol. 2010;184:4033\u201341.","journal-title":"J Immunol"},{"key":"1253_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/ng.547","volume":"42","author":"ME Rothenberg","year":"2010","unstructured":"Rothenberg ME, Spergel JM, Sherrill JD, Annaiah K, Martin LJ, Cianferoni A, et al. Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat Genet. 2010;42:289\u201391.","journal-title":"Nat Genet"},{"key":"1253_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.876515","volume":"13","author":"T Hasegawa","year":"2022","unstructured":"Hasegawa T, Oka T, Demehri S. Alarmin cytokines as central regulators of cutaneous immunity. Front Immunol. 2022;13:876515.","journal-title":"Front Immunol"},{"key":"1253_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","volume":"23","author":"R Ebina-Shibuya","year":"2023","unstructured":"Ebina-Shibuya R, Leonard WJ. Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2023;23:24\u201337.","journal-title":"Nat Rev Immunol"},{"key":"1253_CR24","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.jaci.2017.09.046","volume":"141","author":"LJ Martin","year":"2018","unstructured":"Martin LJ, He H, Collins MH, Abonia JP, Biagini Myers JM, Eby M, et al. Eosinophilic esophagitis (EoE) genetic susceptibility is mediated by synergistic interactions between EoE-specific and general atopic disease loci. J Allergy Clin Immunol. 2018;141:1690\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jaci.2020.10.018","volume":"147","author":"LC Kottyan","year":"2021","unstructured":"Kottyan LC, Trimarchi MP, Lu X, Caldwell JM, Maddox A, Parameswaran S, et al. Replication and meta-analyses nominate numerous eosinophilic esophagitis risk genes. J Allergy Clin Immunol. 2021;147:255\u201366.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR26","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1038\/ncomms6593","volume":"5","author":"PMA Sleiman","year":"2014","unstructured":"Sleiman PMA, Wang M-L, Cianferoni A, Aceves S, Gonsalves N, Nadeau K, et al. GWAS identifies four novel eosinophilic esophagitis loci. Nat Commun. 2014;5:5593.","journal-title":"Nat Commun"},{"key":"1253_CR27","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1172\/JCI26679","volume":"116","author":"C Blanchard","year":"2006","unstructured":"Blanchard C. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest. 2006;116:536\u201347.","journal-title":"J Clin Invest"},{"key":"1253_CR28","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jaci.2013.02.030","volume":"132","author":"JP Abonia","year":"2013","unstructured":"Abonia JP, Wen T, Stucke EM, Grotjan T, Griffith MS, Kemme KA, et al. High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders. J Allergy Clin Immunol. 2013;132:378\u201386.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR29","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.jaci.2016.10.045","volume":"139","author":"C Paluel-Marmont","year":"2017","unstructured":"Paluel-Marmont C, Bellon N, Barbet P, Leclerc-Mercier S, Hadj-Rabia S, Dupont C, et al. Eosinophilic esophagitis and colonic mucosal eosinophilia in Netherton syndrome. J Allergy Clin Immunol. 2017;139:2003\u2013e20051.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR30","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jaci.2015.05.002","volume":"136","author":"MA McAleer","year":"2015","unstructured":"McAleer MA, Pohler E, Smith FJD, Wilson NJ, Cole C, MacGowan S, et al. Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal Plakin domain of Desmoplakin. J Allergy Clin Immunol. 2015;136:1268\u201376.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR31","doi-asserted-by":"publisher","first-page":"e20221755","DOI":"10.1084\/jem.20221755","volume":"220","author":"M Sharma","year":"2023","unstructured":"Sharma M, Leung D, Momenilandi M, Jones LCW, Pacillo L, James AE, et al. Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease. J Exp Med. 2023;220:e20221755.","journal-title":"J Exp Med"},{"key":"1253_CR32","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/nature06096","volume":"448","author":"Y Minegishi","year":"2007","unstructured":"Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448:1058\u201362.","journal-title":"Nature"},{"key":"1253_CR33","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10875-017-0429-z","volume":"37","author":"M Arora","year":"2017","unstructured":"Arora M, Bagi P, Strongin A, Heimall J, Zhao X, Lawrence MG, et al. Gastrointestinal manifestations of STAT3-Deficient Hyper-IgE syndrome. J Clin Immunol. 2017;37:695\u2013700.","journal-title":"J Clin Immunol"},{"key":"1253_CR34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/MPG.0000000000000253","volume":"58","author":"CJ Henderson","year":"2014","unstructured":"Henderson CJ, Ngeow J, Collins MH, Martin LJ, Putnam PE, Abonia JP, et al. Increased prevalence of eosinophilic Gastrointestinal disorders in pediatric PTEN Hamartoma tumor syndromes. J Pediatr Gastroenterol Nutr. 2014;58:553\u201360.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1253_CR35","doi-asserted-by":"publisher","first-page":"e171765","DOI":"10.1172\/jci.insight.171765","volume":"8","author":"MH Clevenger","year":"2023","unstructured":"Clevenger MH, Karami AL, Carlson DA, Kahrilas PJ, Gonsalves N, Pandolfino JE, et al. Suprabasal cells retain progenitor cell identity programs in eosinophilic esophagitis\u2013driven basal cell hyperplasia. JCI Insight. 2023;8:e171765.","journal-title":"JCI Insight"},{"key":"1253_CR36","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/MPG.0000000000000491","volume":"59","author":"A Ravelli","year":"2014","unstructured":"Ravelli A, Villanacci V, Cadei M, Fuoti M, Gennati G, Salemme M. Dilated intercellular spaces in eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2014;59:589\u201393.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1253_CR37","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jaci.2016.11.042","volume":"140","author":"M Rochman","year":"2017","unstructured":"Rochman M, Travers J, Miracle CE, Bedard MC, Wen T, Azouz NP, et al. Profound loss of esophageal tissue differentiation in patients with eosinophilic esophagitis. J Allergy Clin Immunol. 2017;140:738\u2013e7493.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR38","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1152\/ajpgi.00404.2017","volume":"315","author":"L Wu","year":"2018","unstructured":"Wu L, Tadayuki Oshima X, Li M, Tomita T, Fukui H, Watari J, et al. Filaggrin and tight junction proteins are crucial for IL-13-mediated esophageal barrier dysfunction. Am J Physiol Gastrointest Liver Physiol. 2018;315:341\u201350.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1253_CR39","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.cgh.2014.02.039","volume":"12","author":"DA Katzka","year":"2014","unstructured":"Katzka DA, Tadi R, Smyrk TC, Katarya E, Sharma A, Geno DM, et al. Effects of topical steroids on tight junction proteins and spongiosis in esophageal epithelia of patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2014;12:1824\u2013e18291.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1253_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/j.gastro.2019.02.042","volume":"157","author":"A Ravi","year":"2019","unstructured":"Ravi A, Marietta EV, Geno DM, Alexander JA, Murray JA, Katzka DA. Penetration of the esophageal epithelium by dust mite antigen in patients with eosinophilic esophagitis. Gastroenterology. 2019;157:255\u20136.","journal-title":"Gastroenterology"},{"key":"1253_CR41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.anai.2022.10.026","volume":"130","author":"B Underwood","year":"2023","unstructured":"Underwood B, Troutman TD, Schwartz JT. Breaking down the complex pathophysiology of eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2023;130:28\u201339.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1253_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.975914","volume":"13","author":"M Duchesne","year":"2022","unstructured":"Duchesne M, Okoye I, Lacy P. Epithelial cell alarmin cytokines: frontline mediators of the asthma inflammatory response. Front Immunol. 2022;13:975914.","journal-title":"Front Immunol"},{"key":"1253_CR43","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1111\/all.14196","volume":"75","author":"S Toki","year":"2020","unstructured":"Toki S, Goleniewska K, Zhang J, Zhou W, Newcomb DC, Zhou B, et al. TSLP and IL-33 reciprocally promote each other\u2019s lung protein expression and ILC2 receptor expression to enhance innate type-2 airway inflammation. Allergy. 2020;75:1606\u201317.","journal-title":"Allergy"},{"key":"1253_CR44","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.3390\/jcm9113741","volume":"9","author":"M Furue","year":"2020","unstructured":"Furue M. Regulation of skin barrier function via competition between AHR axis versus IL-13\/IL-4\u2013JAK\u2013STAT6\/STAT3 axis: pathogenic and therapeutic implications in atopic dermatitis. JCM. 2020;9:3741.","journal-title":"JCM"},{"key":"1253_CR45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaci.2018.05.008","volume":"142","author":"M Rochman","year":"2018","unstructured":"Rochman M, Azouz NP, Rothenberg ME. Epithelial origin of eosinophilic esophagitis. J Allergy Clin Immunol. 2018;142:10\u201323.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR46","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1136\/gutjnl-2022-327166","volume":"72","author":"T Kaymak","year":"2023","unstructured":"Kaymak T, Kaya B, Wuggenig P, Nuciforo S, G\u00f6ldi A, Swiss EoE Cohort Study Group (SEECS). IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing Filaggrin in eosinophilic oesophagitis. Gut. 2023;72:821\u201333.","journal-title":"Gut"},{"key":"1253_CR47","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/mi.2017.72","volume":"11","author":"N Nguyen","year":"2018","unstructured":"Nguyen N, Fernando SD, Biette KA, Hammer JA, Capocelli KE, Kitzenberg DA, et al. TGF-\u03b21 alters esophageal epithelial barrier function by Attenuation of claudin-7 in eosinophilic esophagitis. Mucosal Immunol. 2018;11:415\u201326.","journal-title":"Mucosal Immunol"},{"key":"1253_CR48","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/MPG.0000000000002144","volume":"68","author":"A Doshi","year":"2019","unstructured":"Doshi A, Khamishon R, Rawson R, Duong L, Dohil L, Myers SJ, et al. Interleukin 9 alters epithelial barrier and E-cadherin in eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2019;68:225\u201331.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1253_CR49","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaci.2015.01.043","volume":"136","author":"KL Pothoven","year":"2015","unstructured":"Pothoven KL, Norton JE, Hulse KE, Suh LA, Carter RG, Rocci E, et al. Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease. J Allergy Clin Immunol. 2015;136:737\u2013e7464.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR50","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.mucimm.2023.06.001","volume":"16","author":"MTA Kleuskens","year":"2023","unstructured":"Kleuskens MTA, Bek MK, Al Halabi Y, Blokhuis BRJ, Diks MAP, Haasnoot ML, et al. Mast cells disrupt the function of the esophageal epithelial barrier. Mucosal Immunol. 2023;16:567\u201377.","journal-title":"Mucosal Immunol"},{"key":"1253_CR51","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-pathol-012615-044241","volume":"11","author":"BP Davis","year":"2016","unstructured":"Davis BP, Rothenberg ME. Mechanisms of disease of eosinophilic esophagitis. Annu Rev Pathol. 2016;11:365\u201393.","journal-title":"Annu Rev Pathol"},{"key":"1253_CR52","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1016\/j.jaci.2022.02.025","volume":"149","author":"N Ben-Baruch Morgenstern","year":"2022","unstructured":"Ben-Baruch Morgenstern N, Ballaban AY, Wen T, Shoda T, Caldwell JM, Kliewer K, et al. Single-cell RNA sequencing of mast cells in eosinophilic esophagitis reveals heterogeneity, local proliferation, and activation that persists in remission. J Allergy Clin Immunol. 2022;149:2062\u201377.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR53","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s12016-019-08769-2","volume":"58","author":"D Elieh Ali Komi","year":"2020","unstructured":"Elieh Ali Komi D, W\u00f6hrl S, Bielory L. Mast cell biology at molecular level: a comprehensive review. Clin Rev Allergy Immunol. 2020;58:342\u201365.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1253_CR54","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.iac.2024.01.004","volume":"44","author":"P Khoury","year":"2024","unstructured":"Khoury P, Wechsler JB. Role of mast cells in eosinophilic gastrointestinal diseases. Immunol Allergy Clin North Am. 2024;44:311\u201327.","journal-title":"Immunol Allergy Clin North Am"},{"key":"1253_CR55","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/s41590-021-01011-2","volume":"22","author":"M Brusilovsky","year":"2021","unstructured":"Brusilovsky M, Rochman M, Rochman Y, Caldwell JM, Mack LE, Felton JM, et al. Environmental allergens trigger type 2 inflammation through Ripoptosome activation. Nat Immunol. 2021;22:1316\u201326.","journal-title":"Nat Immunol"},{"key":"1253_CR56","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.jaci.2024.01.017","volume":"153","author":"MY Masuda","year":"2024","unstructured":"Masuda MY, Pyon GC, Luo H, LeSuer WE, Putikova A, Dao A, et al. Epithelial overexpression of IL-33 induces eosinophilic esophagitis dependent on IL-13. J Allergy Clin Immunol. 2024;153:1355\u201368.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR57","doi-asserted-by":"crossref","unstructured":"Dsilva A, Wagner A, Itan M, Rhone N, Avlas S, Gordon Y et al. Distinct Roles for Thymic Stromal Lymphopoietin (TSLP) and IL-33 in Experimental Eosinophilic Esophagitis. Allergy. 2025.","DOI":"10.1101\/2025.02.25.640192"},{"key":"1253_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01595","volume":"9","author":"G Varricchi","year":"2018","unstructured":"Varricchi G, Pecoraro A, Marone G, Criscuolo G, Spadaro G, Genovese A. Thymic stromal lymphopoietin isoforms, inflammatory disorders, and cancer. Front Immunol. 2018;9:1595.","journal-title":"Front Immunol"},{"key":"1253_CR59","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.4110\/in.2024.24.e6","volume":"24","author":"HY Kim","year":"2024","unstructured":"Kim HY, Jeong D, Kim JH, Chung DH. Innate type-2 cytokines: from immune regulation to therapeutic targets. Immune Netw. 2024;24:e6.","journal-title":"Immune Netw"},{"key":"1253_CR60","doi-asserted-by":"publisher","first-page":"eabi5586","DOI":"10.1126\/sciimmunol.abi5586","volume":"6","author":"DM Morgan","year":"2021","unstructured":"Morgan DM, Ruiter B, Smith NP, Tu AA, Monian B, Stone BE, et al. Clonally expanded, GPR15-expressing pathogenic effector TH2 cells are associated with eosinophilic esophagitis. Sci Immunol. 2021;6:eabi5586.","journal-title":"Sci Immunol"},{"key":"1253_CR61","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jaci.2024.09.024","volume":"155","author":"D Lozano-Ojalvo","year":"2025","unstructured":"Lozano-Ojalvo D, Chen X, Kazmi W, Mench\u00e9n-Mart\u00ednez D, P\u00e9rez-Rodr\u00edguez L, Fernandes-Braga W, et al. Differential T follicular helper cell phenotypes distinguish IgE-mediated milk allergy from eosinophilic esophagitis in children. J Allergy Clin Immunol. 2025;155:909\u201322.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR62","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1111\/all.14854","volume":"76","author":"J Dilollo","year":"2021","unstructured":"Dilollo J, Rodr\u00edguez-L\u00f3pez EM, Wilkey L, Martin EK, Spergel JM, Hill DA. Peripheral markers of allergen-specific immune activation predict clinical allergy in eosinophilic esophagitis. Allergy. 2021;76:3470\u20138.","journal-title":"Allergy"},{"key":"1253_CR63","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.anai.2017.11.006","volume":"120","author":"A Cianferoni","year":"2018","unstructured":"Cianferoni A, Ruffner MA, Guzek R, Guan S, Brown-Whitehorn T, Muir A, et al. Elevated expression of activated TH2 cells and milk-specific TH2 cells in milk-induced eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2018;120:177-183.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1253_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.30","volume":"5","author":"WN Sayej","year":"2016","unstructured":"Sayej WN, M\u00e9noret A, Maharjan AS, Fernandez M, Wang Z, Balarezo F, et al. Characterizing the inflammatory response in esophageal mucosal biopsies in children with eosinophilic esophagitis. Clinical & translational immunology. 2016;5:e88.","journal-title":"Clinical & translational immunology"},{"key":"1253_CR65","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1053\/j.gastro.2020.07.035","volume":"159","author":"MC Manresa","year":"2020","unstructured":"Manresa MC, Chiang AWT, Kurten RC, Dohil R, Brickner H, Dohil L, et al. Increased production of LIGHT by T cells in eosinophilic esophagitis promotes differentiation of esophageal fibroblasts toward an inflammatory phenotype. Gastroenterology. 2020;159:1778-1792.e13.","journal-title":"Gastroenterology"},{"key":"1253_CR66","doi-asserted-by":"publisher","first-page":"S240","DOI":"10.1016\/j.jaci.2006.12.308","volume":"119","author":"C Blanchard","year":"2007","unstructured":"Blanchard C, Mingler MK, Putnam P, Rothenberg ME. Il-13 is overexpressed in eosinophilic esophagitis and induces Eotaxin-3 expression in esophageal epithelial cells. J Allergy Clin Immunol. 2007;119:S240.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR67","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000445215","volume":"43","author":"H Long","year":"2016","unstructured":"Long H, Liao W, Wang L, Lu Q. A player and coordinator: the versatile roles of eosinophils in the immune system. Transfus Med Hemother. 2016;43:96\u2013108.","journal-title":"Transfus Med Hemother"},{"key":"1253_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1470381","volume":"11","author":"A Sanchez Santos","year":"2024","unstructured":"Sanchez Santos A, Socorro Avila I, Galvan Fernandez H, Cazorla Rivero S, Lemes Castellano A, Cabrera Lopez C. Eosinophils: old cells, new directions. Front Med (Lausanne). 2024;11:1470381.","journal-title":"Front Med (Lausanne)"},{"key":"1253_CR69","doi-asserted-by":"publisher","first-page":"e0127755","DOI":"10.1371\/journal.pone.0127755","volume":"10","author":"K Kc","year":"2015","unstructured":"Kc K, Rothenberg ME, Sherrill JD. In vitro model for studying esophageal epithelial differentiation and allergic inflammatory responses identifies keratin involvement in eosinophilic esophagitis. PLoS One. 2015;10:e0127755.","journal-title":"PLoS One"},{"key":"1253_CR70","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1067\/mai.2001.118600","volume":"108","author":"SM Pope","year":"2001","unstructured":"Pope SM, Brandt EB, Mishra A, Hogan SP, Zimmermann N, Matthaei KI, et al. IL-13 induces eosinophil recruitment into the lung by an IL-5\u2013 and eotaxin-dependent mechanism. J Allergy Clin Immunol. 2001;108:594\u2013601.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR71","doi-asserted-by":"publisher","first-page":"799","DOI":"10.4049\/jimmunol.154.2.799","volume":"154","author":"BS Bochner","year":"1995","unstructured":"Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol. 1995;154:799\u2013803.","journal-title":"J Immunol"},{"key":"1253_CR72","doi-asserted-by":"publisher","first-page":"660","DOI":"10.4049\/jimmunol.1000471","volume":"185","author":"L Zuo","year":"2010","unstructured":"Zuo L, Fulkerson PC, Finkelman FD, Mingler M, Fischetti CA, Blanchard C, et al. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R\u03b12\u2013inhibited pathway. J Immunol. 2010;185:660\u20139.","journal-title":"J Immunol"},{"key":"1253_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00139","volume":"4","author":"E Doran","year":"2017","unstructured":"Doran E, Cai F, Holweg CTJ, Wong K, Brumm J, Arron JR. Interleukin-13 in asthma and other eosinophilic disorders. Front Med (Lausanne). 2017;4:139.","journal-title":"Front Med (Lausanne)"},{"key":"1253_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.815842","volume":"12","author":"F Racca","year":"2022","unstructured":"Racca F, Pellegatta G, Cataldo G, Vespa E, Carlani E, Pelaia C, et al. Type 2 inflammation in eosinophilic esophagitis: from pathophysiology to therapeutic targets. Front Physiol. 2022;12:815842.","journal-title":"Front Physiol"},{"key":"1253_CR75","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.gastro.2003.07.007","volume":"125","author":"A Mishra","year":"2003","unstructured":"Mishra A, Rothenberg ME. Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology. 2003;125:1419\u201327.","journal-title":"Gastroenterology"},{"key":"1253_CR76","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1016\/j.biocel.2005.06.010","volume":"37","author":"C Blanchard","year":"2005","unstructured":"Blanchard C, Durual S, Estienne M, Emami S, Vasseur S, Cuber J-C. Eotaxin-3\/CCL26 gene expression in intestinal epithelial cells is up-regulated by interleukin-4 and interleukin-13 via the signal transducer and activator of transcription 6. Int J Biochem Cell Biol. 2005;37:2559\u201373.","journal-title":"Int J Biochem Cell Biol"},{"key":"1253_CR77","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/rr52","volume":"2","author":"DM Conroy","year":"2001","unstructured":"Conroy DM, Williams TJ. Eotaxin and the attraction of eosinophils to the asthmatic lung. Respir Res. 2001;2:150.","journal-title":"Respir Res"},{"key":"1253_CR78","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/gene.2014.27","volume":"15","author":"JD Sherrill","year":"2014","unstructured":"Sherrill JD, Kiran KC, Blanchard C, Stucke EM, Kemme KA, Collins MH, et al. Analysis and expansion of the eosinophilic esophagitis transcriptome by RNA sequencing. Genes Immun. 2014;15:361\u20139.","journal-title":"Genes Immun"},{"key":"1253_CR79","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.dld.2014.03.003","volume":"46","author":"C Romano","year":"2014","unstructured":"Romano C, Chiaro A, Lucarelli S, Santarelli C, Cucchiara S, Guadagnini T, et al. Mucosal cytokine profiles in paediatric eosinophilic oesophagitis: a case-control study. Dig Liver Dis. 2014;46:590\u20135.","journal-title":"Dig Liver Dis"},{"key":"1253_CR80","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/apt.13258","volume":"42","author":"FJ Moawad","year":"2015","unstructured":"Moawad FJ, Wells JM, Johnson RL, Reinhardt BJ, Maydonovitch CL, Baker TP. Comparison of eotaxin-3 biomarker in patients with eosinophilic oesophagitis, proton pump inhibitor-responsive oesophageal eosinophilia and gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2015;42:231\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"1253_CR81","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MPG.0000000000001419","volume":"65","author":"E Politi","year":"2017","unstructured":"Politi E, Angelakopoulou A, Grapsa D, Zande M, Stefanaki K, Panagiotou I, et al. Filaggrin and periostin expression is altered in eosinophilic esophagitis and normalized with treatment. J Pediatr Gastroenterol Nutr. 2017;65:47\u201352.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1253_CR82","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/mi.2008.15","volume":"1","author":"C Blanchard","year":"2008","unstructured":"Blanchard C, Mingler MK, McBride M, Putnam PE, Collins MH, Chang G, et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol. 2008;1:289\u201396.","journal-title":"Mucosal Immunol"},{"key":"1253_CR83","doi-asserted-by":"publisher","first-page":"G1175","DOI":"10.1152\/ajpgi.00313.2012","volume":"303","author":"E Cheng","year":"2012","unstructured":"Cheng E, Souza RF, Spechler SJ. Tissue remodeling in eosinophilic esophagitis. Am J Physiol Gastrointest Liver Physiol. 2012;303:G1175\u20131187.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1253_CR84","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jaci.2012.03.005","volume":"129","author":"AF Kagalwalla","year":"2012","unstructured":"Kagalwalla AF, Akhtar N, Woodruff SA, Rea BA, Masterson JC, Mukkada V, et al. Eosinophilic esophagitis: epithelial mesenchymal transition contributes to esophageal remodeling and reverses with treatment. J Allergy Clin Immunol. 2012;129:1387-1396.e7.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR85","doi-asserted-by":"publisher","first-page":"101466","DOI":"10.1016\/j.jcmgh.2025.101466","volume":"19","author":"M Lal","year":"2025","unstructured":"Lal M, Burk CM, Gautam R, Mrozek Z, Canziani KE, Trachsel T, et al. Interferon-\u03b3 signaling in eosinophilic esophagitis affects epithelial barrier function and programmed cell death. Cell Mol Gastroenterol Hepatol. 2025;19:101466.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"1253_CR86","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1067\/mai.2001.119917","volume":"108","author":"A Straumann","year":"2001","unstructured":"Straumann A, Bauer M, Fischer B, Blaser K, Simon HU. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol. 2001;108:954\u201361.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR87","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.yexcr.2012.12.002","volume":"319","author":"AB Muir","year":"2013","unstructured":"Muir AB, Lim DM, Benitez AJ, Modayur Chandramouleeswaran P, Lee AJ, Ruchelli ED, et al. Esophageal epithelial and mesenchymal cross-talk leads to features of epithelial to mesenchymal transition in vitro. Exp Cell Res. 2013;319:850\u20139.","journal-title":"Exp Cell Res"},{"key":"1253_CR88","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00535-018-1498-3","volume":"54","author":"AB Muir","year":"2019","unstructured":"Muir AB, Wang JX, Nakagawa H. Epithelial-stromal crosstalk and fibrosis in eosinophilic esophagitis. J Gastroenterol. 2019;54:10\u20138.","journal-title":"J Gastroenterol"},{"key":"1253_CR89","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jaci.2015.03.031","volume":"136","author":"AM Collison","year":"2015","unstructured":"Collison AM, Sokulsky LA, Sherrill JD, Nightingale S, Hatchwell L, Talley NJ, et al. TNF-related apoptosis-inducing ligand (TRAIL) regulates midline-1, thymic stromal lymphopoietin, inflammation, and remodeling in experimental eosinophilic esophagitis. J Allergy Clin Immunol. 2015;136:971\u201382.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR90","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.bpg.2015.09.012","volume":"29","author":"J Leung","year":"2015","unstructured":"Leung J, Beukema KR, Shen AH. Allergic mechanisms of eosinophilic oesophagitis. Best Pract Res Clin Gastroenterol. 2015;29:709\u201320.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"1253_CR91","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/MPG.0000000000002227","volume":"68","author":"AE Pope","year":"2019","unstructured":"Pope AE, Stanzione N, Naini BV, Garcia-Lloret M, Ghassemi KA, Marcus EA, et al. Esophageal IgG4: Clinical, Endoscopic, and histologic correlations in eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2019;68:689\u201394.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1253_CR92","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1111\/all.13486","volume":"73","author":"CE Rosenberg","year":"2018","unstructured":"Rosenberg CE, Mingler MK, Caldwell JM, Collins MH, Fulkerson PC, Morris DW, et al. Esophageal IgG4 levels correlate with histopathologic and transcriptomic features in eosinophilic esophagitis. Allergy. 2018;73:1892\u2013901.","journal-title":"Allergy"},{"key":"1253_CR93","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1111\/all.15826","volume":"78","author":"JG Medernach","year":"2023","unstructured":"Medernach JG, Li R-C, Zhao X-Y, Yin B, Noonan EA, Etter EF, et al. Immunoglobulin G4 in eosinophilic esophagitis: immune complex formation and correlation with disease activity. Allergy. 2023;78:3193\u2013203.","journal-title":"Allergy"},{"key":"1253_CR94","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.anai.2022.10.004","volume":"130","author":"QM Nhu","year":"2023","unstructured":"Nhu QM, Aceves SS. Current state of biologics in treating eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2023;130:15\u201320.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1253_CR95","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13543784.2022.2033207","volume":"31","author":"S Tamarit-Sebastian","year":"2022","unstructured":"Tamarit-Sebastian S, Ferrer-Soler FM, Lucendo AJ. Current options and investigational drugs for the treatment of eosinophilic esophagitis. Expert Opin Investig Drugs. 2022;31:193\u2013210.","journal-title":"Expert Opin Investig Drugs"},{"key":"1253_CR96","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/ajg.2012.468","volume":"108","author":"KA Peterson","year":"2013","unstructured":"Peterson KA, Byrne KR, Vinson LA, Ying J, Boynton KK, Fang JC, et al. Elemental diet induces histologic response in adult eosinophilic esophagitis. Am J Gastroenterol. 2013;108:759\u201366.","journal-title":"Am J Gastroenterol"},{"key":"1253_CR97","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11894-013-0364-y","volume":"16","author":"KA Peterson","year":"2014","unstructured":"Peterson KA, Boynton KK. Which patients with eosinophilic esophagitis (EoE) should receive elemental diets versus other therapies? Curr Gastroenterol Rep. 2014;16:364.","journal-title":"Curr Gastroenterol Rep"},{"key":"1253_CR98","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000357077","volume":"32","author":"BK Ballmer-Weber","year":"2014","unstructured":"Ballmer-Weber BK. Value of allergy tests for the diagnosis of food allergy. Dig Dis. 2014;32:84\u20138.","journal-title":"Dig Dis"},{"key":"1253_CR99","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/apt.13676","volume":"44","author":"H Philpott","year":"2016","unstructured":"Philpott H, Nandurkar S, Royce SG, Thien F, Gibson PR. Allergy tests do not predict food triggers in adult patients with eosinophilic oesophagitis. A comprehensive prospective study using five modalities. Aliment Pharmacol Ther. 2016;44:223\u201333.","journal-title":"Aliment Pharmacol Ther"},{"key":"1253_CR100","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S2468-1253(23)00012-2","volume":"8","author":"KL Kliewer","year":"2023","unstructured":"Kliewer KL, Gonsalves N, Dellon ES, Katzka DA, Abonia JP, Aceves SS, et al. One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial. Lancet Gastroenterol Hepatol. 2023;8:408\u201321.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1253_CR101","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jaci.2024.08.023","volume":"155","author":"KL Kliewer","year":"2025","unstructured":"Kliewer KL, Abonia JP, Aceves SS, Atkins D, Bonis PA, Capocelli KE, et al. One-food versus 4-food elimination diet for pediatric eosinophilic esophagitis: A multisite randomized trial. J Allergy Clin Immunol. 2025;155:520\u201332.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR102","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/2050640616689525","volume":"5","author":"AJ Lucendo","year":"2017","unstructured":"Lucendo AJ, Molina-Infante J, Arias \u00c1, Von Arnim U, Bredenoord AJ, Bussmann C, et al. Guidelines on eosinophilic esophagitis: evidence\u2010based statements and recommendations for diagnosis and management in children and adults. UEG J. 2017;5:335\u201358.","journal-title":"UEG J"},{"key":"1253_CR103","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cgh.2015.07.041","volume":"14","author":"AJ Lucendo","year":"2016","unstructured":"Lucendo AJ, Arias \u00c1, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:13-e221.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1253_CR104","doi-asserted-by":"crossref","unstructured":"Lucendo AJ, Guti\u00e9rrez-Ram\u00edrez L, Tejera-Mu\u00f1oz A, Molina-Infante J, Arias \u00c1. Proton Pump Inhibitors for Inducing and Maintaining Remission in Eosinophilic Esophagitis: An Updated Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology. 2025;S1542356525001880.","DOI":"10.1016\/j.cgh.2025.01.016"},{"key":"1253_CR105","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2147\/JAA.S274524","volume":"15","author":"JP Franciosi","year":"2022","unstructured":"Franciosi JP, Mougey EB, Dellon ES, Gutierrez-Junquera C, Fernandez-Fernandez S, Venkatesh RD, et al. Proton pump inhibitor therapy for eosinophilic esophagitis: History, Mechanisms, Efficacy, and future directions. J Asthma Allergy. 2022;15:281\u2013302.","journal-title":"J Asthma Allergy"},{"key":"1253_CR106","doi-asserted-by":"publisher","first-page":"e50037","DOI":"10.1371\/journal.pone.0050037","volume":"7","author":"X Zhang","year":"2012","unstructured":"Zhang X, Cheng E, Huo X, Yu C, Zhang Q, Pham TH, et al. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS One. 2012;7:e50037.","journal-title":"PLoS One"},{"key":"1253_CR107","doi-asserted-by":"crossref","unstructured":"Gautam R, Lal M, Carroll MC, Mrozek Z, Trachsel T, Beers J et al. Proton pump inhibitors modulate esophageal epithelial barrier function and crosstalk with eosinophils. BioRxiv. 2024;2024.08.22.609219.","DOI":"10.1101\/2024.08.22.609219"},{"key":"1253_CR108","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jaci.2014.08.043","volume":"135","author":"T Wen","year":"2015","unstructured":"Wen T, Dellon ES, Moawad FJ, Furuta GT, Aceves SS, Rothenberg ME. Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation. J Allergy Clin Immunol. 2015;135:187\u201397.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR109","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jaci.2016.07.020","volume":"139","author":"J-Y Min","year":"2017","unstructured":"Min J-Y, Ocampo CJ, Stevens WW, Price CPE, Thompson CF, Homma T, et al. Proton pump inhibitors decrease eotaxin-3\/CCL26 expression in patients with chronic rhinosinusitis with nasal polyps: possible role of the nongastric H,K-ATPase. J Allergy Clin Immunol. 2017;139:130\u2013e14111.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR110","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/MPG.0000000000002480","volume":"69","author":"EB Mougey","year":"2019","unstructured":"Mougey EB, Williams A, Coyne AJK, Guti\u00e9rrez-Junquera C, Fern\u00e1ndez-Fern\u00e1ndez S, Cilleruelo ML, et al. CYP2C19 and STAT6 variants influence the outcome of proton pump inhibitor therapy in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2019;69:581\u20137.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1253_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16040487","volume":"16","author":"L Rodr\u00edguez-Alcolado","year":"2024","unstructured":"Rodr\u00edguez-Alcolado L, Navarro P, Arias-Gonz\u00e1lez L, Grueso-Navarro E, Lucendo AJ, Laserna-Mendieta EJ. Proton-pump inhibitors in eosinophilic esophagitis: a review focused on the role of pharmacogenetics. Pharmaceutics. 2024;16:487.","journal-title":"Pharmaceutics"},{"key":"1253_CR112","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.iac.2023.12.010","volume":"44","author":"GW Falk","year":"2024","unstructured":"Falk GW, Pesek R. Pharmacologic management of eosinophilic esophagitis. Immunol Allergy Clin North Am. 2024;44:245\u201364.","journal-title":"Immunol Allergy Clin North Am"},{"key":"1253_CR113","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1053\/j.gastro.2020.02.039","volume":"158","author":"MA Rank","year":"2020","unstructured":"Rank MA, Sharaf RN, Furuta GT, Aceves SS, Greenhawt M, Spergel JM, et al. Technical review on the management of eosinophilic esophagitis: A report from the AGA Institute and the joint task force on Allergy-Immunology practice parameters. Gastroenterology. 2020;158:1789\u2013e181015.","journal-title":"Gastroenterology"},{"key":"1253_CR114","doi-asserted-by":"publisher","first-page":"815842","DOI":"10.3389\/fphys.2021.815842","volume":"12","author":"F Racca","year":"2021","unstructured":"Racca F, Pellegatta G, Cataldo G, Vespa E, Carlani E, Pelaia C, et al. Type 2 inflammation in eosinophilic esophagitis: from pathophysiology to therapeutic targets. Front Physiol. 2021;12:815842.","journal-title":"Front Physiol"},{"key":"1253_CR115","doi-asserted-by":"publisher","first-page":"31","DOI":"10.14309\/ajg.0000000000003194","volume":"120","author":"ES Dellon","year":"2025","unstructured":"Dellon ES, Muir AB, Katzka DA, Shah SC, Sauer BG, Aceves SS, et al. ACG clinical guideline: diagnosis and management of eosinophilic esophagitis. Am J Gastroenterol. 2025;120:31\u201359.","journal-title":"Am J Gastroenterol"},{"key":"1253_CR116","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/all.12096","volume":"68","author":"A Straumann","year":"2013","unstructured":"Straumann A, Hoesli S, Bussmann C, Stuck M, Perkins M, Collins LP, et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy. 2013;68:375\u201385.","journal-title":"Allergy"},{"key":"1253_CR117","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1398-9995.2009.02142.x","volume":"65","author":"SS Aceves","year":"2010","unstructured":"Aceves SS, Newbury RO, Chen D, Mueller J, Dohil R, Hoffman H, et al. Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids. Allergy. 2010;65:109\u201316.","journal-title":"Allergy"},{"key":"1253_CR118","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1053\/j.gastro.2012.04.049","volume":"143","author":"ES Dellon","year":"2012","unstructured":"Dellon ES, Sheikh A, Speck O, Woodward K, Whitlow AB, Hores JM, et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology. 2012;143:321\u2013e3241.","journal-title":"Gastroenterology"},{"key":"1253_CR119","doi-asserted-by":"publisher","first-page":"139","DOI":"10.18176\/jiaci.0254","volume":"28","author":"J Sastre","year":"2018","unstructured":"Sastre J, D\u00e1vila I, Dupilumab. A new paradigm for the treatment of allergic diseases. J Investig Allergol Clin Immunol. 2018;28:139\u201350.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"1253_CR120","doi-asserted-by":"publisher","first-page":"7240","DOI":"10.1073\/pnas.0802465105","volume":"105","author":"A Munitz","year":"2008","unstructured":"Munitz A, Brandt EB, Mingler M, Finkelman FD, Rothenberg ME. Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci U S A. 2008;105:7240\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1253_CR121","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1016\/j.cgh.2023.07.025","volume":"21","author":"DL Snyder","year":"2023","unstructured":"Snyder DL, Dellon ES. Biologics in the treatment of eosinophilic esophagitis: ready for use? Clin Gastroenterol Hepatol. 2023;21:3230\u20133.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1253_CR122","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/1750743X.2024.2377060","volume":"16","author":"EP Syverson","year":"2024","unstructured":"Syverson EP, Rubinstein E, Lee JJ, McDonald DR, Hait E. The role of dupilumab in the treatment of eosinophilic esophagitis. Immunotherapy. 2024;16:845\u201352.","journal-title":"Immunotherapy"},{"key":"1253_CR123","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S2468-1253(23)00204-2","volume":"8","author":"ME Rothenberg","year":"2023","unstructured":"Rothenberg ME, Dellon ES, Collins MH, Hirano I, Chehade M, Bredenoord AJ, et al. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8:990\u20131004.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1253_CR124","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1056\/NEJMoa2312282","volume":"390","author":"M Chehade","year":"2024","unstructured":"Chehade M, Dellon ES, Spergel JM, Collins MH, Rothenberg ME, Pesek RD, et al. Dupilumab for eosinophilic esophagitis in patients 1 to 11 years of age. N Engl J Med. 2024;390:2239\u201351.","journal-title":"N Engl J Med"},{"key":"1253_CR125","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","volume":"387","author":"ES Dellon","year":"2022","unstructured":"Dellon ES, Rothenberg ME, Collins MH, Hirano I, Chehade M, Bredenoord AJ, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387:2317\u201330.","journal-title":"N Engl J Med"},{"key":"1253_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031702","volume":"25","author":"E Ridolo","year":"2024","unstructured":"Ridolo E, Barone A, Ottoni M, Peveri S, Montagni M, Nicoletta F. The new therapeutic frontiers in the treatment of eosinophilic esophagitis: biological drugs. Int J Mol Sci. 2024;25:1702.","journal-title":"Int J Mol Sci"},{"key":"1253_CR127","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/MOG.0000000000000842","volume":"38","author":"AL Strauss","year":"2022","unstructured":"Strauss AL, Falk GW. Refractory eosinophilic esophagitis: what to do when the patient has not responded to proton pump inhibitors, steroids and diet. Curr Opin Gastroenterol. 2022;38:395\u2013401.","journal-title":"Curr Opin Gastroenterol"},{"key":"1253_CR128","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/intimm\/dxp102","volume":"21","author":"T Kouro","year":"2009","unstructured":"Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009;21:1303\u20139.","journal-title":"Int Immunol"},{"key":"1253_CR129","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1136\/gutjnl-2023-330337","volume":"72","author":"ES Dellon","year":"2023","unstructured":"Dellon ES, Peterson KA, Mitlyng BL, Iuga A, Bookhout CE, Cortright LM, et al. Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Gut. 2023;72:1828\u201337.","journal-title":"Gut"},{"key":"1253_CR130","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/gut.2009.178558","volume":"59","author":"A Straumann","year":"2010","unstructured":"Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut. 2010;59:21\u201330.","journal-title":"Gut"},{"key":"1253_CR131","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","volume":"129","author":"JM Spergel","year":"2012","unstructured":"Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129:456\u201363. 463.e1-3.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR132","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/MPG.0000000000001840","volume":"66","author":"JE Markowitz","year":"2018","unstructured":"Markowitz JE, Jobe L, Miller M, Frost C, Laney Z, Eke R. Safety and efficacy of reslizumab for children and adolescents with eosinophilic esophagitis treated for 9 years. J Pediatr Gastroenterol Nutr. 2018;66:893\u20137.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1253_CR133","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2313318","volume":"390","author":"ME Rothenberg","year":"2024","unstructured":"Rothenberg ME, Dellon ES, Collins MH, Bredenoord AJ, Hirano I, Peterson KA, et al. Eosinophil depletion with benralizumab for eosinophilic esophagitis. N Engl J Med. 2024;390:2252\u201363.","journal-title":"N Engl J Med"},{"key":"1253_CR134","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2147\/DDDT.S155307","volume":"12","author":"C Pelaia","year":"2018","unstructured":"Pelaia C, Vatrella A, Bruni A, Terracciano R, Pelaia G. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Des Devel Ther. 2018;12:619\u201328.","journal-title":"Drug Des Devel Ther"},{"key":"1253_CR135","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.pharmthera.2012.06.005","volume":"135","author":"T Kiwamoto","year":"2012","unstructured":"Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther. 2012;135:327\u201336.","journal-title":"Pharmacol Ther"},{"key":"1253_CR136","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.14309\/01.ajg.0000858424.48968.ad","volume":"117","author":"E Dellon","year":"2022","unstructured":"Dellon E, Chehade M, Genta RM, Leiman DA, Peterson KA, Spergel J, et al. S446 results from KRYPTOS, a phase 2\/3 study of lirentelimab (AK002) in adults and adolescents with EoE. Am J Gastroenterol. 2022;117:e316\u20137.","journal-title":"Am J Gastroenterol"},{"key":"1253_CR137","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.14309\/01.ajg.0000858436.90680.1a","volume":"117","author":"E Dellon","year":"2022","unstructured":"Dellon E, Chehade M, Genta RM, Leiman DA, Peterson KA, Spergel J, et al. S449 lirentelimab (AK002) safety and efficacy in patients with higher eosinophil thresholds: supplementary analysis of phase 2\/3 EoE KRYPTOS trial. Am J Gastroenterol. 2022;117:e318\u20139.","journal-title":"Am J Gastroenterol"},{"key":"1253_CR138","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1136\/gutjnl-2023-329873","volume":"72","author":"P Visaggi","year":"2023","unstructured":"Visaggi P, Barberio B, Del Corso G, de Bortoli N, Black CJ, Ford AC, et al. Comparison of drugs for active eosinophilic oesophagitis: systematic review and network meta-analysis. Gut. 2023;72:2019\u201330.","journal-title":"Gut"},{"key":"1253_CR139","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/all.15585","volume":"78","author":"D Terhorst-Molawi","year":"2023","unstructured":"Terhorst-Molawi D, Hawro T, Grekowitz E, Kiefer L, Merchant K, Alvarado D, et al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2023;78:1269\u201379.","journal-title":"Allergy"},{"key":"1253_CR140","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","volume":"135","author":"ME Rothenberg","year":"2015","unstructured":"Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015;135:500\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR141","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/1744666X.2019.1705784","volume":"16","author":"AJ Lucendo","year":"2020","unstructured":"Lucendo AJ. Pharmacological treatments for eosinophilic esophagitis: current options and emerging therapies. Expert Rev Clin Immunol. 2020;16:63\u201377.","journal-title":"Expert Rev Clin Immunol"},{"key":"1253_CR142","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","volume":"156","author":"I Hirano","year":"2019","unstructured":"Hirano I, Collins MH, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer AM, et al. RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis. Gastroenterology. 2019;156:592-603.e10.","journal-title":"Gastroenterology"},{"key":"1253_CR143","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.cgh.2020.03.036","volume":"19","author":"ES Dellon","year":"2021","unstructured":"Dellon ES, Collins MH, Rothenberg ME, Assouline-Dayan Y, Evans L, Gupta S, et al. Long-term efficacy and tolerability of RPC4046 in an Open-Label extension trial of patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2021;19:473\u2013e48317.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1253_CR144","unstructured":"Celgene A, Phase. 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects With Eosinophilic Esophagitis [Internet]. clinicaltrials.gov; 2025 Feb. Report No.: NCT04753697. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04753697"},{"key":"1253_CR145","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.2217\/imt-2023-0079","volume":"15","author":"M Shinkai","year":"2023","unstructured":"Shinkai M, Yabuta T. Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma. Immunotherapy. 2023;15:1435\u201347.","journal-title":"Immunotherapy"},{"key":"1253_CR146","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40265-022-01679-2","volume":"82","author":"SM Hoy","year":"2022","unstructured":"Hoy SM. Tezepelumab: first approval. Drugs. 2022;82:461\u20138.","journal-title":"Drugs"},{"key":"1253_CR147","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1016\/j.jaip.2024.08.013","volume":"12","author":"CS Sharlin","year":"2024","unstructured":"Sharlin CS, Collins MH, Bolton SM, Osswald GA, Safadi GS, Kliewer KL, et al. Induction of sustained remission and reversal of pathologic transcriptome achieved with tezepelumab in an adolescent with eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2024;12:3147\u2013e31492.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1253_CR148","unstructured":"Efficacy. and Safety of Tezepelumab in Patients with Eosinophilic Esophagitis [Internet]. [cited 2025 Aug 27]. Available from: https:\/\/www.astrazenecaclinicaltrials.com\/study\/D5244C00001"},{"key":"1253_CR149","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","volume":"208","author":"J Corren","year":"2023","unstructured":"Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, et al. Efficacy of tezepelumab in Severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208:13\u201324.","journal-title":"Am J Respir Crit Care Med"},{"key":"1253_CR150","doi-asserted-by":"publisher","first-page":"e0113483","DOI":"10.1371\/journal.pone.0113483","volume":"10","author":"D Loizou","year":"2015","unstructured":"Loizou D, Enav B, Komlodi-Pasztor E, Hider P, Kim-Chang J, Noonan L, et al. A pilot study of Omalizumab in eosinophilic esophagitis. PLoS One. 2015;10:e0113483.","journal-title":"PLoS One"},{"key":"1253_CR151","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1053\/j.gastro.2014.05.036","volume":"147","author":"F Clayton","year":"2014","unstructured":"Clayton F, Fang JC, Gleich GJ, Lucendo AJ, Olalla JM, Vinson LA, et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology. 2014;147:602\u20139.","journal-title":"Gastroenterology"},{"key":"1253_CR152","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/phar.2783","volume":"43","author":"PD Meek","year":"2023","unstructured":"Meek PD, Hemstreet B. Emerging therapies for eosinophilic esophagitis. Pharmacotherapy. 2023;43:338\u201348.","journal-title":"Pharmacotherapy"},{"key":"1253_CR153","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cgh.2016.09.013","volume":"15","author":"JA Alexander","year":"2017","unstructured":"Alexander JA, Ravi K, Enders FT, Geno DM, Kryzer LA, Mara KC, et al. Montelukast does not maintain symptom remission after topical steroid therapy for eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2017;15:214\u2013e2212.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1253_CR154","first-page":"199","volume":"9","author":"AM Schoepfer","year":"2024","unstructured":"Schoepfer AM, Safroneeva E. Pharmacologic treatment of eosinophilic esophagitis: efficacious, likely efficacious, and failed drugs. Inflamm Intest Dis. 2024;9:199\u2013209.","journal-title":"Inflamm Intest Dis"},{"key":"1253_CR155","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jaci.2008.06.012","volume":"122","author":"A Straumann","year":"2008","unstructured":"Straumann A, Bussmann C, Conus S, Beglinger C, Simon H-U. Anti\u2013TNF-\u03b1 (infliximab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol. 2008;122:425\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"1253_CR156","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/jpn3.70007","volume":"80","author":"M Wu","year":"2025","unstructured":"Wu M, Glickman JN, Winter HS. Eosinophilic esophagitis associated with Infliximab therapy in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2025;80:807\u201311.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1253_CR157","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.cgh.2018.06.022","volume":"16","author":"TH Taft","year":"2018","unstructured":"Taft TH, Mutlu EA. The potential role of vedolizumab in concomitant eosinophilic esophagitis and crohn\u2019s disease. Clin Gastroenterol Hepatol. 2018;16:1840\u20131.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1253_CR158","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1007\/s10620-019-05704-5","volume":"64","author":"ILP Beales","year":"2019","unstructured":"Beales ILP. Resolution of refractory eosinophilic esophagitis with the leukocyte-trafficking inhibitor natalizumab. Dig Dis Sci. 2019;64:2688\u20139.","journal-title":"Dig Dis Sci"},{"key":"1253_CR159","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/00325481.2024.2320081","volume":"136","author":"CM Antequera","year":"2024","unstructured":"Antequera CM, Orleck K, Jacob R, Kenneally A, Wright WL. Potassium-competitive acid blockers: rethinking acid suppression for gastroesophageal reflux disease and Helicobacter pylori. Postgrad Med. 2024;136:131\u201340.","journal-title":"Postgrad Med"},{"key":"1253_CR160","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s10388-020-00783-0","volume":"18","author":"T Kuzumoto","year":"2021","unstructured":"Kuzumoto T, Tanaka F, Sawada A, Nadatani Y, Otani K, Hosomi S, et al. Vonoprazan shows efficacy similar to that of proton pump inhibitors with respect to symptomatic, endoscopic, and histological responses in patients with eosinophilic esophagitis. Esophagus. 2021;18:372\u20139.","journal-title":"Esophagus"},{"key":"1253_CR161","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/ajg.2016.167","volume":"111","author":"N Ishimura","year":"2016","unstructured":"Ishimura N, Ishihara S, Kinoshita Y. Sustained acid suppression by potassium-competitive acid blocker (P-CAB) may be an attractive treatment candidate for patients with eosinophilic esophagitis. Am J Gastroenterol. 2016;111:1203\u20134.","journal-title":"Am J Gastroenterol"},{"key":"1253_CR162","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085(24)01011-4","volume":"166","author":"A Bredenoord","year":"2024","unstructured":"Bredenoord A, Houbiers JG, Vanuytsel T, Chvatchko Y, Hoff DA, Conchillo JM, et al. 962 caly-002, an anti-il-15 antibody, results in histological and clinical improvement in patients with eosinophilic esophagitis in a phase 1a\/b study. Gastroenterology. 2024;166:S\u2013228.","journal-title":"Gastroenterology"},{"key":"1253_CR163","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/19420862.2017.1332553","volume":"9","author":"AP Vicari","year":"2017","unstructured":"Vicari AP, Schoepfer AM, Meresse B, Goffin L, L\u00e9ger O, Josserand S, et al. Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory Celiac disease and eosinophilic esophagitis. MAbs. 2017;9:927\u201344.","journal-title":"MAbs"},{"key":"1253_CR164","doi-asserted-by":"publisher","first-page":"e0157376","DOI":"10.1371\/journal.pone.0157376","volume":"11","author":"E Cheng","year":"2016","unstructured":"Cheng E, Zhang X, Wilson KS, Wang DH, Park JY, Huo X, et al. JAK-STAT6 pathway inhibitors block eotaxin-3 secretion by epithelial cells and fibroblasts from esophageal eosinophilia patients: promising agents to improve inflammation and prevent fibrosis in EoE. PLoS One. 2016;11:e0157376.","journal-title":"PLoS One"},{"key":"1253_CR165","doi-asserted-by":"publisher","first-page":"e232558","DOI":"10.1136\/bcr-2019-232558","volume":"12","author":"LB Mendoza Alvarez","year":"2019","unstructured":"Mendoza Alvarez LB, Liu X, Glover S. Treatment-resistant eosinophilic oesophagitis successfully managed with Tofacitinib. BMJ Case Rep. 2019;12:e232558.","journal-title":"BMJ Case Rep"},{"key":"1253_CR166","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00403-024-03578-w","volume":"317","author":"O Lamberg","year":"2024","unstructured":"Lamberg O, Pandher K, Troost JP, Lim HW. Long-term adverse event risks of oral JAK inhibitors versus immunomodulators: a literature review. Arch Dermatol Res. 2024;317:109.","journal-title":"Arch Dermatol Res"},{"key":"1253_CR167","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S2468-1253(25)00062-7","volume":"10","author":"ES Dellon","year":"2025","unstructured":"Dellon ES, Collins MH, Bredenoord AJ, Philpott H, Biedermann L, Dulcine M, et al. Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2025;10:622\u201333.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1253_CR168","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1053\/j.gastro.2017.06.065","volume":"154","author":"KM O\u2019Shea","year":"2018","unstructured":"O\u2019Shea KM, Aceves SS, Dellon ES, Gupta SK, Spergel JM, Furuta GT, et al. Pathophysiology of eosinophilic esophagitis. Gastroenterology. 2018;154:333\u201345.","journal-title":"Gastroenterology"},{"key":"1253_CR169","doi-asserted-by":"publisher","first-page":"e00164","DOI":"10.14309\/ctg.0000000000000164","volume":"11","author":"QM Nhu","year":"2020","unstructured":"Nhu QM, Hsieh L, Dohil L, Dohil R, Newbury RO, Kurten R, et al. Antifibrotic effects of the thiazolidinediones in eosinophilic esophagitis pathologic remodeling: a preclinical evaluation. Clin Transl Gastroenterol. 2020;11:e00164.","journal-title":"Clin Transl Gastroenterol"},{"key":"1253_CR170","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jot.2021.03.005","volume":"29","author":"Z Deng","year":"2021","unstructured":"Deng Z, Chen F, Liu Y, Wang J, Lu W, Jiang W, et al. Losartan protects against osteoarthritis by repressing the TGF-\u03b21 signaling pathway via upregulation of PPAR\u03b3. J Orthop Translat. 2021;29:30\u201341.","journal-title":"J Orthop Translat"},{"key":"1253_CR171","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/187221310789895649","volume":"4","author":"L Masuelli","year":"2010","unstructured":"Masuelli L, Tumino G, Turriziani M, Modesti A, Bei R. Topical use of sucralfate in epithelial wound healing: clinical evidences and molecular mechanisms of action. Recent Pat Inflamm Allergy Drug Discov. 2010;4:25\u201336.","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"1253_CR172","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1172\/JCI126744","volume":"129","author":"JC Masterson","year":"2019","unstructured":"Masterson JC, Biette KA, Hammer JA, Nguyen N, Capocelli KE, Saeedi BJ, et al. Epithelial HIF-1\u03b1\/claudin-1 axis regulates barrier dysfunction in eosinophilic esophagitis. J Clin Invest. 2019;129:3224\u201335.","journal-title":"J Clin Invest"},{"key":"1253_CR173","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1111\/all.15069","volume":"77","author":"MTA Kleuskens","year":"2022","unstructured":"Kleuskens MTA, Haasnoot ML, Herpers BM, van Ampting MTJ, Bredenoord AJ, Garssen J, et al. Butyrate and propionate restore Interleukin 13-compromised esophageal epithelial barrier function. Allergy. 2022;77:1510\u201321.","journal-title":"Allergy"},{"key":"1253_CR174","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz7773","volume":"12","author":"NP Azouz","year":"2020","unstructured":"Azouz NP, Klingler AM, Pathre P, Besse JA, Baruch-Morgenstern NB, Ballaban AY, et al. Functional role of kallikrein 5 and proteinase-activated receptor 2 in eosinophilic esophagitis. Sci Transl Med. 2020;12:eaaz7773.","journal-title":"Sci Transl Med"},{"key":"1253_CR175","first-page":"CD004065","volume":"7","author":"JP Franciosi","year":"2023","unstructured":"Franciosi JP, Gordon M, Sinopoulou V, Dellon ES, Gupta SK, Reed CC, et al. Medical treatment of eosinophilic esophagitis. Cochrane Database Syst Rev. 2023;7:CD004065.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01253-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-026-01253-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01253-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:51:52Z","timestamp":1781639512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-026-01253-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":175,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1253"],"URL":"https:\/\/doi.org\/10.1007\/s11882-026-01253-w","relation":{},"ISSN":["1534-6315"],"issn-type":[{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a review of existing studies and does not contain any new studies with human or animal subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Ravi Gautam declares no conflicts of interest. Melanie Ruffner reports funded research from Regeneron, the National Institute of Allergy and Infectious Diseases, and the Children\u2019s Hospital of Philadelphia Frontier Program.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"21"}}